On February 12, 2024, Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, announced the closing of its previously announced underwritten public offering for total gross proceeds of approximately $189.75 million. Wilson Sonsini Goodrich & Rosati advised Sana Biotechnology on the transaction.

In the public offering, Sana sold 21,772,728 shares of its common stock at $5.50 each, which includes the full exercise of the underwriters’ option to purchase an additional 4,500,000 shares. Additionally, in lieu of common stock to certain investors, pre-funded warrants to purchase 12,727,272 shares were sold at $5.4999 per pre-funded warrant.

Morgan Stanley, J.P. Morgan, Goldman Sachs & Co. LLC, and BofA Securities acted as joint book-running managers for the offering.

The Wilson Sonsini team that advised Sana Biotechnology in the offering included Tony Jeffries, Jennifer Knapp, Phil McGill, Tyler Kivley, Alison Sechrest, and Alex Manter.

For more information, please see Sana Biotechnology's news release.